Axonal Transport Dysfunction Validation in Parkinson's Disease

Axonal Transport Dysfunction Validation in Parkinson's Disease

Experiment Overview

Hypothesis: Axonal transport dysfunction is an upstream driver of dopaminergic neurodegeneration in Parkinson's Disease.

Objective: Validate axonal transport as therapeutic target through multi-phase preclinical and clinical studies.

Study Design

Phase 1: In Vitro Validation (12 months)

Objective: Establish axonal transport defect mechanisms in PD models

Axonal Transport Dysfunction Validation in Parkinson's Disease

Experiment Overview

Hypothesis: Axonal transport dysfunction is an upstream driver of dopaminergic neurodegeneration in Parkinson's Disease.

Objective: Validate axonal transport as therapeutic target through multi-phase preclinical and clinical studies.

Study Design

Phase 1: In Vitro Validation (12 months)

Objective: Establish axonal transport defect mechanisms in PD models

| Endpoint | Method | Samples |
|----------|--------|---------|
| Anterograde transport rate | Live-cell imaging (kinesin-mCherry) | iPSC-DA neurons (n=20 PD, 20 controls) |
| Retrograde transport rate | Live-cell imaging (dynein-GFP) | iPSC-DA neurons (n=20 PD, 20 controls) |
| Mitochondrial distribution | Mitotracker + confocal microscopy | iPSC-DA neurons (n=15/group) |
| Motor protein levels | Western blot | iPSC-DA neurons (n=10/group) |
| Microtubule integrity | Acetylated tubulin immunostaining | iPSC-DA neurons (n=10/group) |

Interventions:

• Microtubule stabilizers (Taxol, 10-100 nM)
• Kinesin activators
• Dynein modulators
• Miro1 overexpression

Phase 2: Preclinical Validation (18 months)

Objective: Validate therapeutic approaches in animal models

Model: AAV-α-synuclein + LRRK2 G2019S mice (n=80)

| Endpoint | Method | Timepoint |
|----------|--------|-----------|
| Transport velocity in vivo | Two-photon imaging (cortical neurons) | Month 3, 6, 9 |
| Mitochondrial density in axons | EM morphometry | Month 6, 12 |
| Behavioral assessment | Rotarod, gait analysis, cylinder test | Monthly |
| Dopaminergic neuron survival | Stereology (TH+ count) | Endpoint |
| Axonal integrity | PNF silver staining | Endpoint |

Treatment Arms:

Phase 3: Clinical Biomarker Study (24 months)

Objective: Validate transport biomarkers in PD patients

Population: Early-stage PD (n=150), age-matched controls (n=50)

| Endpoint | Method |
|----------|--------|
| CSF kinesin light chain | ELISA |
| CSF dynein heavy chain | ELISA |
| Peripheral transport assay | Lymphocyte migration |
| Clinical progression | MDS-UPDRS (baseline, 12mo, 24mo) |

Inclusion Criteria

• Age 40-75 years
• PD diagnosis <3 years
• Hoehn & Yahr stage 1-2.5
• No significant cognitive impairment (MoCA >24)
• Able to undergo lumbar puncture

Outcome Measures

Primary

• Change in CSF transport protein levels at 12 months
• Correlation with motor progression (MDS-UPDRS part III)

Secondary

• Axonal integrity markers (NFL, phosphorylated tau)
• Quality of life measures (PDQ-39)
• Biomarker validation for future clinical trials

Statistical Analysis

• Mixed-effects model for longitudinal endpoints
• Power: 80% to detect 30% difference in transport markers
• Multiplicity adjustment for secondary endpoints

Risk Assessment

| Risk | Mitigation |
|------|------------|
| Microtubule stabilization toxicity | Start with low doses, monitor liver function |
| Variable transport measurements | Centralized assay standardization |
| Patient dropout | Regular follow-up, engagement strategies |

Budget Estimate

• Phase 1: $800,000
• Phase 2: $1,200,000
• Phase 3: $600,000
• Total: $2.6 million

Timeline

| Phase | Duration | Milestone |
|-------|----------|-----------|
| Phase 1 | 12 months | Validated iPSC transport assay |
| Phase 2 | 18 months | Lead compound identified |
| Phase 3 | 24 months | Biomarker validation complete |

Next Steps